FormuMax provides specialized contract research services focused on liposomes and lipid nanoparticles (LNPs). Our team collaborates with pharmaceutical, biotechnology, and academic researchers to develop stable, reproducible formulations suitable for preclinical research and development.
We support projects ranging from early feasibility studies to optimized liposome/LNP formulations. Our work integrates formulation development, and analytical characterization to accelerate the development of lipid-based delivery systems.
Our laboratory combines extensive formulation experience with advanced analytical instrumentation to support the development of lipid-based drug delivery systems.
Over the past 18 years, more than 100 biotechnology and pharmaceutical and government organizations have collaborated with FormuMax.
In addition, over 1,500 research laboratories worldwide have used our liposome reagents in scientific studies.
Liposome formulation R&D.
LNP formulation for mRNA delivery
Scale-up and process optimization
Liposome & LNP surface modification |
Analytical & characterization

FormuMax develops custom liposomal formulations tailored to the requirements of each project. We work with clients to design lipid compositions that achieve optimal encapsulation efficiency, particle size control, and formulation stability.
Typical projects include:
• small molecule drug encapsulation
• peptide and protein delivery
• imaging agents and diagnostic probes
• immunology and macrophage research reagents

FormuMax develops lipid nanoparticles for nucleic acid delivery, including mRNA, siRNA, and plasmid DNA.
Our LNP development services focus on achieving:
• efficient nucleic acid encapsulation
• controlled particle size and narrow size distribution
• optimized lipid compositions
• stable formulations suitable for in vitro and in vivo studies

Efficient drug loading is essential for effective liposome formulations. FormuMax provides specialized expertise in optimizing encapsulation strategies for a wide range of molecules.
Optimization studies may include:
• passive and active loading approaches
• lipid composition screening
• drug-to-lipid ratio optimization
• formulation stability evaluation

FormuMax develops lipid nanoparticles for nucleic acid delivery, including mRNA, siRNA, and plasmid DNA.
Our LNP development services focus on achieving:
• efficient nucleic acid encapsulation
• controlled particle size and narrow size distribution
• optimized lipid compositions
• stable formulations suitable for in vitro and in vivo studies

FormuMax provides analytical characterization services to evaluate the quality and performance of lipid nanoparticles.
Our laboratory performs:
• particle size and size distribution analysis
• nanoparticle concentration measurement
• zeta potential characterization
• encapsulation efficiency determination
• formulation stability studies
These analytical services can be performed as part of formulation development or as stand-alone characterization studies for client-supplied samples.

FormuMax also produces specialized liposome reagents widely used in research in university labs.
FormuMax liposome reagents have been cited in over 500 scientific publications.